Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Renew Dental Diminishes Fear by Protecting Patients and Staff From COVID-19 Using Surfacide’s Proven UV Technology

FOR IMMEDIATE RELEASE Renew Dental is the first dental practice in the United States to adopt Surfacide–a powerful and innovative technology to combat COVID-19 head on and provide a safer environment for patients and staff. The leading Phoenix dental facility is using Surfacide’s proven UV-C system to decontaminate surfaces to address the concerns of SARS-CoV-2…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Renew Dental Diminishes Fear by Protecting Patients and Staff From COVID-19 Using Surfacide’s Proven UV Technology

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

FOR IMMEDIATE RELEASE

Renew Dental is the first dental practice in the United States to adopt Surfacide–a powerful and innovative technology to combat COVID-19 head on and provide a safer environment for patients and staff. The leading Phoenix dental facility is using Surfacide’s proven UV-C system to decontaminate surfaces to address the concerns of SARS-CoV-2 and COVID-19.

Staff at Renew Dental were pleasantly surprised to see the technology at work, decontaminating patient rooms in as little as five minutes. Dr. Gwen Multine, DMD, discovered the Surfacide system when researching UV technology and knew her patients and workers would be appreciative in the dental practices’ investment in their safety.

“Our office is perfect for the Surfacide system. When the pandemic began, we were looking for something that would not just give the illusion of safety or spray chemicals into the air,” says Dr. Gwen Multine. “Surfacide accomplishes that while making our patients and technicians feel safer.”

Surfacide is being used to decontaminate rooms daily and Renew Dental has not reported any positive COVID-19 cases since its implementation. Each day, Renew Dental’s EVS team runs Surfacide in the exam rooms, cleans the space by hand and runs the Surfacide system once more for an additional layer of protection. The Surfacide system is the first of its kind to use a triple emitter UV-C technology to laser map the room and significantly reduce the presence of viruses and bacteria in a single, rapid cycle.

“Renew Dental is a unique partner of ours as they are the first dental office in the U.S. to implement Surfacide’s technology, and we are very impressed with their proactive infection prevention initiatives to address COVID-19,” says Gunner Lyslo, Founder and CEO of Surfacide. “COVID-19 has made critical healthcare tasks like visiting the dentist something that many may delay doing for fear of the current pandemic. Surfacide and clinics like Renew dental are here to reduce that fear and provide a sense of normalcy back to everyday life.”

About Surfacide LLC

Surfacide LLC and Surfacide Manufacturing Inc., are located in Waukesha, WI and produce multiple emitter UV-C systems.

Surfacide is the only triple emitter UV-C system, providing the most efficient and flexible solution in the fight against viruses and other hospital-acquired infections. Over 400 hospitals nationally and internationally are using Surfacide technology to provide an extra layer of protection for patients

and healthcare workers. Surfacide’s evidence-based UV-C solution addresses shadows and provides greater coverage for quicker turnaround time and better care. Patients and healthcare workers around the world choose Surfacide as a trusted partner in infection prevention.

Our mission is to provide patients and healthcare workers with a safe environment and continuous support in infection prevention. We respect and admire the dedication from healthcare professionals and in turn, deliver advanced technology that your team needs to provide the best care possible. Learn more about Surfacide by visiting https://surfacide.com or calling (844)-390-3538.

For More Information Contact

Sarah Kotlan | Marketing Coordinator Surfacide, LLC (262) 501-4900 | sarah.kotlan@surfacide.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

The EU’s MDR delay buys time, but it won’t clear your commissioning bottleneck

The European Commission backed extending EU MDR transition deadlines to December 2027 and December 2028, Medical Design & Outsourcing reported. It buys time, not ramp-up capacity. Design News cites digital commissioning and machine digital twins to cut “power-on” surprises and speed validation and operator training.

  • 01If an EU portfolio includes Class III, December 2027 is now the planning anchor, but the internal gating item may shift to validation capacity and automation readiness, not paperwork.
  • 02Digital commissioning is becoming a procurement spec, not a buzzword, because it lets teams run DFM/DFA learning loops before hardware is built, which Design News notes is meant to reduce machine power-on surprises.

Sep 5, 2026

HCA’s Q1 was not about volume. It was about coverage and collecting cash

HCA Healthcare reaffirmed 2026 guidance after Q1 weather and a muted respiratory season cut adjusted EBITDA by about $180 million, according to HealthLeaders and Fierce Healthcare. Payer mix shifted fast. Exchange admissions fell about 15% and uninsured admissions rose about 16%, Fierce reported.

  • 01A mild flu season can be a margin event: HCA tied a 42% drop in respiratory admissions to a roughly $180M adjusted EBITDA hit (HealthLeaders, Fierce Healthcare).
  • 02The 2026 risk is sliding from demand to coverage: HCA cited a $600M–$900M full-year EBITDA headwind from exchange-related changes, with $150M already in Q1 (HealthLeaders, Fierce Healthcare).
  • 03Supplemental payments are becoming an operating capability, not a windfall: HCA said Q1 Medicaid program net benefit was about $200M vs $80M expected (HealthLeaders, Fierce Healthcare), putting state-by-state reimbursement strategy on the CFO’s critical path.

Sep 5, 2026

Dental practice exits are turning into multi-year projects, not last-year decisions

Dental practice exits are turning into multi-year projects, not last-year decisions

Associate-led dental practice successions can take 3–5+ years. Dental Economics says associate-to-buyout timelines often run three to five-plus years. That pushes revenue-cycle controls, buy-sell terms, and tax structure earlier, before a buyer appears.

  • 01A practical benchmark is emerging for succession: bringing in an associate with intent to buy can take a minimum of three years and often more than five, according to Dental Economics.
  • 02If accounts receivable looks “high,” it may be a bookkeeping and posting problem before it is a payer problem, a revenue-cycle diagnostic Group Dentistry Now says shows up frequently at scale.
  • 03Exit planning is now an operating system project: valuation, tax positioning, and transition support belong in the same workstream, because deal structure can lock in or foreclose tax options, per Dental Economics.

Sep 4, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512